{"id":"NCT00667251","sponsor":"Novartis Pharmaceuticals","briefTitle":"Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer","officialTitle":"A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-07","primaryCompletion":"2012-08-01","completion":"2022-07-27","firstPosted":"2008-04-28","resultsPosted":"2014-06-18","lastUpdate":"2025-03-21"},"enrollment":652,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"trastuzumab","otherNames":[]},{"type":"DRUG","name":"docetaxel","otherNames":[]},{"type":"DRUG","name":"lapatinib ditosylate","otherNames":[]},{"type":"DRUG","name":"paclitaxel","otherNames":[]}],"arms":[{"label":"Lapatinib","type":"ACTIVE_COMPARATOR"},{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR"}],"summary":"This was a multi-center, multinational, randomized, open-label, Phase III study comparing combination taxane-based chemotherapy plus lapatinib to combination taxane-based chemotherapy plus trastuzumab in women with documented evidence of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) (by local or central laboratory testing) who had received no prior chemotherapy or HER2 targeted therapy in the metastatic setting.","primaryOutcome":{"measure":"Progression Free Survival (PFS) at the Time of Primary Results","timeFrame":"From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to approximately 39 months","effectByArm":[{"arm":"Lapatinib (LTax/L)","deltaMin":8.97,"sd":null},{"arm":"Trastuzumab (TTax/T)","deltaMin":11.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"},{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":257,"countries":["United States","Argentina","Australia","Belgium","Canada","France","Germany","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["25779558","28484925","28750133"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":106,"n":322},"commonTop":["Alopecia","Fatigue","Diarrhoea","Peripheral sensory neuropathy","Rash"]}}